Immunogenicity and safety of SARS-CoV-2 (COVID-19 virus) vaccine in patients with hepatocellular carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210525005

Enrollment

Registered

2021-05-25

Start date

2021-06-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunogenicity and safety of SARS-CoV-2 vaccine in patients with hepatocellular carcinoma COVID-19, vaccine, hepatocellular carcinoma, SARS-CoV-2

Interventions

Patients with hepatocellular carcinoma in HCC clinic

Prevention

Patients with hepatocellular carcinoma

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with hepatocellular carcinoma

Exclusion criteria

Exclusion criteria: 1. Anaphylaxis to SARS-CoV-2 vaccine 2. Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Immunogenicity of SARS-CoV-2 vaccine 6 months SARS-CoV-2 antibody	—

Secondary

Measure	Time frame
Safety of SARS-CoV-2 vaccine 6 months Patient reported adverse events	—

Countries

Thailand

Contacts

Public ContactSupachaya Sriphoosanaphan

Faculty of Medicine, Chulalongkorn University

supachaya.sr@gmail.com022564691

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026